Mucosal Melanoma

News alerts, weekly reports and conference planners

Related cancers:

‹

Melanoma (1043)

Ocular Melanoma (111)

Uveal Melanoma (106)

Cutaneous Melanoma (86)

Melanoma (1043)

Ocular Melanoma (111)

Uveal Melanoma (106)

Cutaneous Melanoma (86)

›

No biomarker	Mucosal Melanoma	No biomarker	Mucosal Melanoma	toripalimab-tpzi Sensitive: B - Late Trials toripalimab-tpzi Sensitive : B	toripalimab-tpzi Sensitive: B - Late Trials toripalimab-tpzi Sensitive : B
No biomarker	Mucosal Melanoma	No biomarker	Mucosal Melanoma	ALKS 4230 Sensitive: B - Late Trials ALKS 4230 Sensitive : B	ALKS 4230 Sensitive: B - Late Trials ALKS 4230 Sensitive : B
CDK4 amplification	Mucosal Melanoma	CDK4 amplification	Mucosal Melanoma	dalpiciclib Sensitive: C2 – Inclusion Criteria dalpiciclib Sensitive : C2	dalpiciclib Sensitive: C2 – Inclusion Criteria dalpiciclib Sensitive : C2
BRAF mutation	Mucosal Melanoma	BRAF mutation	Mucosal Melanoma	PD1 inhibitor Sensitive: C3 – Early Trials PD1 inhibitor Sensitive : C3	PD1 inhibitor Sensitive: C3 – Early Trials PD1 inhibitor Sensitive : C3
KIT mutation	Mucosal Melanoma	KIT mutation	Mucosal Melanoma	PD1 inhibitor Sensitive: C3 – Early Trials PD1 inhibitor Sensitive : C3	PD1 inhibitor Sensitive: C3 – Early Trials PD1 inhibitor Sensitive : C3
MDM2 amplification	Mucosal Melanoma	MDM2 amplification	Mucosal Melanoma	ipilimumab Resistant: C3 – Early Trials ipilimumab Resistant : C3	ipilimumab Resistant: C3 – Early Trials ipilimumab Resistant : C3
MDM4 amplification	Mucosal Melanoma	MDM4 amplification	Mucosal Melanoma	ipilimumab Resistant: C3 – Early Trials ipilimumab Resistant : C3	ipilimumab Resistant: C3 – Early Trials ipilimumab Resistant : C3
MDM2 amplification	Mucosal Melanoma	MDM2 amplification	Mucosal Melanoma	nivolumab + ipilimumab Resistant: C3 – Early Trials nivolumab + ipilimumab Resistant : C3	nivolumab + ipilimumab Resistant: C3 – Early Trials nivolumab + ipilimumab Resistant : C3
MDM2 amplification	Mucosal Melanoma	MDM2 amplification	Mucosal Melanoma	nivolumab Resistant: C3 – Early Trials nivolumab Resistant : C3	nivolumab Resistant: C3 – Early Trials nivolumab Resistant : C3
MDM4 amplification	Mucosal Melanoma	MDM4 amplification	Mucosal Melanoma	nivolumab + ipilimumab Resistant: C3 – Early Trials nivolumab + ipilimumab Resistant : C3	nivolumab + ipilimumab Resistant: C3 – Early Trials nivolumab + ipilimumab Resistant : C3
MDM4 amplification	Mucosal Melanoma	MDM4 amplification	Mucosal Melanoma	nivolumab Resistant: C3 – Early Trials nivolumab Resistant : C3	nivolumab Resistant: C3 – Early Trials nivolumab Resistant : C3
EGFR amplification	Mucosal Melanoma	EGFR amplification	Mucosal Melanoma	ipilimumab Resistant: C3 – Early Trials ipilimumab Resistant : C3	ipilimumab Resistant: C3 – Early Trials ipilimumab Resistant : C3
EGFR amplification	Mucosal Melanoma	EGFR amplification	Mucosal Melanoma	nivolumab Resistant: C3 – Early Trials nivolumab Resistant : C3	nivolumab Resistant: C3 – Early Trials nivolumab Resistant : C3
EGFR amplification	Mucosal Melanoma	EGFR amplification	Mucosal Melanoma	nivolumab + ipilimumab Resistant: C3 – Early Trials nivolumab + ipilimumab Resistant : C3	nivolumab + ipilimumab Resistant: C3 – Early Trials nivolumab + ipilimumab Resistant : C3
EGFR amplification	Mucosal Melanoma	EGFR amplification	Mucosal Melanoma	pembrolizumab Resistant: C3 – Early Trials pembrolizumab Resistant : C3	pembrolizumab Resistant: C3 – Early Trials pembrolizumab Resistant : C3
MDM4 amplification	Mucosal Melanoma	MDM4 amplification	Mucosal Melanoma	pembrolizumab Resistant: C3 – Early Trials pembrolizumab Resistant : C3	pembrolizumab Resistant: C3 – Early Trials pembrolizumab Resistant : C3
MDM2 amplification	Mucosal Melanoma	MDM2 amplification	Mucosal Melanoma	pembrolizumab Resistant: C3 – Early Trials pembrolizumab Resistant : C3	pembrolizumab Resistant: C3 – Early Trials pembrolizumab Resistant : C3
NRAS mutation	Mucosal Melanoma	NRAS mutation	Mucosal Melanoma	PD1 inhibitor Resistant: C3 – Early Trials PD1 inhibitor Resistant : C3	PD1 inhibitor Resistant: C3 – Early Trials PD1 inhibitor Resistant : C3
BRAF mutation	Mucosal Melanoma	BRAF mutation	Mucosal Melanoma	cisplatin + dacarbazine Sensitive: C3 – Early Trials cisplatin + dacarbazine Sensitive : C3	cisplatin + dacarbazine Sensitive: C3 – Early Trials cisplatin + dacarbazine Sensitive : C3
NRAS mutation	Mucosal Melanoma	NRAS mutation	Mucosal Melanoma	cisplatin + temozolomide Sensitive: C3 – Early Trials cisplatin + temozolomide Sensitive : C3	cisplatin + temozolomide Sensitive: C3 – Early Trials cisplatin + temozolomide Sensitive : C3
KIT mutation	Mucosal Melanoma	KIT mutation	Mucosal Melanoma	temozolomide Sensitive: C3 – Early Trials temozolomide Sensitive : C3	temozolomide Sensitive: C3 – Early Trials temozolomide Sensitive : C3
BRAF mutation	Mucosal Melanoma	BRAF mutation	Mucosal Melanoma	cisplatin + temozolomide Sensitive: C3 – Early Trials cisplatin + temozolomide Sensitive : C3	cisplatin + temozolomide Sensitive: C3 – Early Trials cisplatin + temozolomide Sensitive : C3
NRAS mutation	Mucosal Melanoma	NRAS mutation	Mucosal Melanoma	cisplatin + dacarbazine Sensitive: C3 – Early Trials cisplatin + dacarbazine Sensitive : C3	cisplatin + dacarbazine Sensitive: C3 – Early Trials cisplatin + dacarbazine Sensitive : C3
KIT mutation	Mucosal Melanoma	KIT mutation	Mucosal Melanoma	cisplatin + dacarbazine Sensitive: C3 – Early Trials cisplatin + dacarbazine Sensitive : C3	cisplatin + dacarbazine Sensitive: C3 – Early Trials cisplatin + dacarbazine Sensitive : C3
PD-L1 expression	Mucosal Melanoma	PD-L1 expression	Mucosal Melanoma	toripalimab-tpzi Sensitive: C3 – Early Trials toripalimab-tpzi Sensitive : C3	toripalimab-tpzi Sensitive: C3 – Early Trials toripalimab-tpzi Sensitive : C3
KIT exon 17 mutation	Mucosal Melanoma	KIT exon 17 mutation	Mucosal Melanoma	avapritinib Sensitive: C3 – Early Trials avapritinib Sensitive : C3	avapritinib Sensitive: C3 – Early Trials avapritinib Sensitive : C3
CTAG1B overexpression	Mucosal Melanoma	CTAG1B overexpression	Mucosal Melanoma	nivolumab + ipilimumab Sensitive: C3 – Early Trials nivolumab + ipilimumab Sensitive : C3	nivolumab + ipilimumab Sensitive: C3 – Early Trials nivolumab + ipilimumab Sensitive : C3
MAGEA4 overexpression	Mucosal Melanoma	MAGEA4 overexpression	Mucosal Melanoma	nivolumab + ipilimumab Sensitive: C3 – Early Trials nivolumab + ipilimumab Sensitive : C3	nivolumab + ipilimumab Sensitive: C3 – Early Trials nivolumab + ipilimumab Sensitive : C3
MAGEA3 overexpression	Mucosal Melanoma	MAGEA3 overexpression	Mucosal Melanoma	nivolumab + ipilimumab Sensitive: C3 – Early Trials nivolumab + ipilimumab Sensitive : C3	nivolumab + ipilimumab Sensitive: C3 – Early Trials nivolumab + ipilimumab Sensitive : C3
KIT L576P	Mucosal Melanoma	KIT L576P	Mucosal Melanoma	sorafenib Resistant: C4 – Case Studies sorafenib Resistant : C4	sorafenib Resistant: C4 – Case Studies sorafenib Resistant : C4
KIT L576P	Mucosal Melanoma	KIT L576P	Mucosal Melanoma	temsirolimus Resistant: C4 – Case Studies temsirolimus Resistant : C4	temsirolimus Resistant: C4 – Case Studies temsirolimus Resistant : C4
KIT L576P	Mucosal Melanoma	KIT L576P	Mucosal Melanoma	imatinib Resistant: C4 – Case Studies imatinib Resistant : C4	imatinib Resistant: C4 – Case Studies imatinib Resistant : C4

Mucosal Melanoma

Associations(33)

Associations
(33)